DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations
DURECT Sells ALZET Osmotic Pumps for $17.5M, Pays Off Loan Obligations
DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm.
Durect Corporation（納斯達克股票代碼：DRRX）是一家處於後期階段的生物製藥公司，該公司率先開發表觀遺傳學療法，以改變急性器官損傷等嚴重和危及生命的疾病的治療方法。該公司今天宣佈將其AlZet系列滲透泵出售給拉斐特儀器有限公司。(LIC)，一家專注於北美的私募股權公司Branford Castle Partners II, L.P. 旗下的投資組合公司。
) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation () is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer.">
）是一家處於後期階段的生物製藥公司，率先開發針對失調的DNA甲基化的表觀遺傳學療法，以改變包括急性器官損傷和癌症在內的嚴重和危及生命的疾病的治療方法。” alt= “Durect Corporation () 是一家後期生物製藥公司，率先開發針對失調的DNA甲基化的表觀遺傳學療法，以改變包括急性器官損傷和癌症在內的嚴重和危及生命的疾病的治療。“>
Under the terms of the agreement, LIC paid DURECT $17.5 million in exchange for certain assets and liabilities associated with the ALZET product line. Simultaneous with this transaction, DURECT has paid off all remaining obligations under the term loan agreement with Oxford Finance LLC.
根據協議條款，LIC向Durect支付了1750萬美元，以換取與AlZet產品系列相關的某些資產和負債。在這筆交易的同時，Durect還清了與牛津金融有限責任公司簽訂的定期貸款協議下的所有剩餘債務。
